Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 3/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1065451 | 0.87 | GAA (0.47) | CCR2EPHX1GAAALDH1A1POLB | |
| SCHEMBL2979314 | 0.86 | GAA (0.65) | CCR2EPHX1GAAALDH1A1POLB | |
| SCHEMBL2987304 | 0.86 | GAA (0.46) | CCR2EPHX1GAAALDH1A1POLB | |
| SCHEMBL3316845 | 0.83 | ALOX15 (0.44) | CCR2GAAPOLBKMT2ASMN1; SMN2 | |
| SCHEMBL5172985 | 0.83 | ALOX15 (0.44) | CCR2GAAPOLBKMT2ASMN1; SMN2 | |
| SCHEMBL3318233 | 0.81 | HPGD (0.37) | CCR2GAAALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL3316925 | 0.80 | CCR2 (0.60) | CCR2EPHX1ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL3802103 | 0.77 | CCR2 (0.92) | CCR2EPHX1ALDH1A1POLBRAB9A | |
| SCHEMBL12292042 | 0.77 | CCR2 (0.92) | CCR2EPHX1ALDH1A1POLBRAB9A | |
| SCHEMBL16064908 | 0.77 | GAA (0.66) | CCR2EPHX1GAAALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497261-B2 | 3-aminocaprolactam compounds for treating inflammatory disorders | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2013-07-30 | — | — | US | claimed |
| EP-1781299-B1 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE ENTPR LTD (GB) | 2010-12-22 | — | — | EP | claimed |
| US-20100292213-A1 | Anti-Inflammatory Agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-11-18 | — | — | US | claimed |
| US-7691845-B2 | Anti-inflammatory agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-04-06 | — | — | US | claimed |
| US-20080194541-A1 | Anti-Inflammatory Agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2008-08-14 | — | — | US | claimed |
| EP-2401611-B1 | IMPROVED METHODS FOR IDENTIFICATION | CAMBRIDGE ENTPR LTD (GB) | 2013-11-06 | — | — | EP | disclosed |
| US-20130203734-A1 | ANTI-INFLAMMATORY AGENTS | GRAINGER DAVID JOHN (GB) | 2013-08-08 | — | — | US | disclosed |
| US-8497261-B2 | 3-aminocaprolactam compounds for treating inflammatory disorders | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2013-07-30 | — | — | US | disclosed |
| US-20120115742-A1 | METHODS FOR IDENTIFICATION | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2012-05-10 | — | — | US | disclosed |
| US-20120053076-A1 | METHODS FOR IDENTIFICATION | CAMBRIDGE ENTERPRISE LIMITED | 2012-03-01 | — | — | US | disclosed |
| EP-1781299-B1 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE ENTPR LTD (GB) | 2010-12-22 | — | — | EP | disclosed |
| US-20100292213-A1 | Anti-Inflammatory Agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-11-18 | — | — | US | disclosed |
| US-7691845-B2 | Anti-inflammatory agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| US-20080194541-A1 | Anti-Inflammatory Agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
| EP-1896036-A1 | ANTI-INFLAMMATORY AGENTS | Cambridge Enterprise Limited (GB) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006134384-A1 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194541-A1 | Anti-Inflammatory Agents | TNF, IL1RN, FPR1 | CCR2 96/4885EPHX1 1819/4885GAA 1896/4885 |
| US-20130203734-A1 | ANTI-INFLAMMATORY AGENTS | IL6, TNF, IL1B | CCR2 94/4885EPHX1 1152/4885GAA 2059/4885 |
| US-20100292213-A1 | Anti-Inflammatory Agents | TNF, IL1RN, IL1R1 | CCR2 121/4885EPHX1 1677/4885GAA 1878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.